Heather M. Schneider is a partner in the Intellectual Property Department. Heather’s practice focuses on patent litigation, as well as antitrust issues involving intellectual property. Her litigation experience encompasses an array of technologies, including pharmaceuticals and biologic products, computer software, medical devices, and chemical products. Her practice also includes client counseling on patent issues, as well as intellectual property issues associated with transactional work including licensing, mergers, and bankruptcy.
In the pharmaceutical field, Heather has played a significant role in a recent collaboration agreement regarding a promising COVID-19 treatment and in litigations and appeals for major life sciences companies involving drug products including: erythropoietin (Epogen), dexmedetomidine (Precedex), rotigotine (Neupro), fingolimod (Gilenya), paricalcitol (Zemplar), oxycodone HCI (OxyContin), argatroban (Argatroban Injection), and amlodipine besylate (Norvasc). She was lead counsel in obtaining a preliminary injunction for breach of contract and other claims for a matter involving agricultural fertilizers. In the computer field, Heather appeared before the U.S. and Canadian courts in the Nortel bankruptcy litigation involving the allocation of proceeds from the sale of Nortel's $4.5 billion portfolio of telecommunications patents.